Granulocyte colony-stimulating factor and its receptor

G. D. Demetri, JD Griffin

Blood

GranulocyteHematologyImmunologyBlood CellGranulocyte Colony-stimulating Factor +4

Granulocyte colony-stimulating factor and its receptor

G. D. Demetri, JD Griffin

Blood

GranulocyteHematologyImmunologyBlood CellGranulocyte Colony-stimulating Factor +4

Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro

G. D. Demetri, BW Zenzie, JG Rheinwald, +1

Blood

Regulation of Granulocyte- and Monocyte-colony Stimulating Factor mRNA Levels in Human Blood Monocytes Is Mediated Primarily at a Post-transcriptional Level

T J Ernst, Alec Ritchie, G. D. Demetri, +1

Journal of Biological Chemistry

G-csf TranscriptsImmunologyImmune RegulationPathologyMrna Half-life +17

Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST

G. D. Demetri, A.T. van Oosterom, Martin E. Blackstein, +7

Journal of Clinical Oncology

PathologyPlacebo-controlled TrialTumor BiologyImatinib ResistanceImatinib Therapy +14

Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - Phase III Sarcoma Group Study S0033

Cathryn Rankin, Margaret von Mehren, Charles D. Blanke, +6

Journal of Clinical Oncology

Metastatic GistSurgical OncologyMedicineDose EffectMetronomic Therapy +13

Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.

I Tepler, S A Cannistra, Emil Frei, +7

Journal of Clinical Oncology

Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with <i>KIT</i> and <i>PDGFRA</i> mutation status

Michael C. Heinrich, Robert G. Maki, Christopher L. Corless, +6

Journal of Clinical Oncology

Tumor BiologyTumoral PathologyOncologyMalignant DiseaseMedicine +13

Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST).

Margaret von Mehren, Michael C. Heinrich, Heikki Joensuu, +3

Journal of Clinical Oncology

Surgical OncologyImmunodeficienciesGist GenotypesImmunologyPathology +17

Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT).

Sant P. Chawla, Jean‐Yves Blay, I. L. Ray-Coquard, +16

Journal of Clinical Oncology

Mtor Inhibitor RidaforolimusAdvanced Sarcoma PatientsPfs EventsMedicinePhase Iii +13